Clinical trial · Observational
Metabolic Changes in Prostate Cancer Patients With Androgen-ablation Therapy (AAT)
NCT01284608CI-TRIAL-00008738UROCORcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is an observational, prospective, non-interventional and multi-centre study, to assess the impact of androgen ablation therapy in blood triglycerides, cholesterol and glucose, body fat distribution and fracture risk to ten years using FRAX model in patients with prostate cancer. The patients will be following for 12 months
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostatic Cancer | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (6)
- measure
- Metabolic syndrome
- timeFrame
- 3 months
- measure
- Metabolic syndrome
- timeFrame
- 6 months
- measure
- Metabolic syndrome
- timeFrame
- 12 months
- measure
- Diabetes
- timeFrame
- 3 months
- measure
- Diabetes
- timeFrame
- 6 months
- measure
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Prostate cancer patient requiring androgen-ablation treatment: LHRH analogs, surgical castration, antiandrogen treatment * Provision of informed consent prior to conducting any study-related procedure Exclusion Criteria: * Patient involved in a Clinical Trial
References
Publications (0)
Data not yet available
No reference posted for this study.